20:37 , Feb 6, 2019 |  BC Innovations  |  Translation in Brief

Testing cognition without bias

Cognetivity Neurosciences Ltd. has developed an image-based cognitive function test that avoids the confounding biases inherent to standard tests and uses artificial intelligence (AI) to interpret the results. The test could enable better detection of...
16:03 , Feb 5, 2019 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An image-based test of cognitive function could help diagnose cognitive impairment, a sign of Alzheimer’s disease, mild cognitive impairment (MCI) and other neurological indications. The Integrative Cognition Assessment (ICA) test is delivered...
20:30 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting ACE could help treat lupus-associated cognitive dysfunction. In hippocampal tissue samples from a mouse model of the indication, ACE expression was higher than in samples from normal mice....
20:24 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Omeros' OMS721 underwhelms in Phase II for IgA nephropathy

Omeros Corp. (NASDAQ:OMER) reported data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for 12 weeks led to a 0.4% greater reduction in median proteinuria...
19:53 , Oct 5, 2018 |  BC Week In Review  |  Financial News

Delta-Fly raises ¥3.3B in IPO

Cancer company Delta-Fly Pharma Inc. (Tokyo:4598) raised ¥3.3 billion ($29.3 million) in IPO on Oct. 3 through the sale of 700,000 shares at ¥4,770. The price values the company at ¥20.5 billion ($180.1 million). Delta-Fly...
23:38 , Oct 2, 2018 |  BC Extra  |  Clinical News

Omeros' OMS721 underwhelms in Phase II

Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721...
22:23 , Sep 21, 2018 |  BioCentury  |  Finance

Flying Delta in Japan

That Delta-Fly Pharma Inc. is slated to become only the third biotech to go public on Tokyo Stock Exchange’s Mothers in three years is the latest reminder that tough listing standards are still making it...
16:15 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

J&J planning submission for Invokana in CKD following Phase III readout

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
22:10 , Jul 16, 2018 |  BC Extra  |  Clinical News

J&J planning submission for Invokana in CKD

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat...